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Abstract. Glipizide is a second generation of sulfonylurea with promising hypoglycemic 
activity. It acts by stimulating the release of insulin from β-cells of pancreas. Glipizide is 
absorbed rapidly, uniformly with good mean oral bioavailability. It offers several advantages 
such as swift and short action, high potency and also does not accumulate in plasma on repeated 
oral administration. In this paper we report the acute and subacute toxicity of glipizide on 
BALB/c albino mice. The results showed the safety of our synthesized product. 
Keywords: acute, glipizide, hypoglycemia, subacute, sulfonylurea, toxicity. 
Classification numbers: 2.3.1;  2.7.1;  2.10.2. 
1. INTRODUCTION 
Glipizide (Fig. 1) is a second generation of sulfonylurea which lowers the blood glucose 
levels in patient suffering from non-insulin dependent diabetes mellitus (NIDDM). It acts by 
stimulating insulin secretion of the pancreatic islets and several other extra pancreatic effects, 
such as enhancing sensitivity to insulin, decreasing the hepatic glucose production [1-2]. 
Glipizide is completely absorbed from the gastrointestinal tract and metabolized into five 
different metabolites in the liver, and has a half-life between 2.5 and 4.7 hours [3]. Glipizide is 
one of the most effective insulin secretogogue both in the primary phase of insulin secretion and 
in sustained stimulatory response during long term administration [4]. Consequently, it is one of 
the most commonly prescribed drugs for treatment of type 2 diabetes mellitus [5]. Its main 
features are swift and short action with a very high selectivity [6, 7]. It is also regarded as 100 
times more effective than tolbutamide in evoking pancreatic secretion of insulin [8].  
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The acute and subchronic toxicity of glipizide were evaluated. The acute oral toxicity was 
extremely low in all species tested (LD50 greater than 4 g/kg) [9, 10]. Subchronic toxicity was 
evaluated in rats at oral doses up to 8 mg/kg/day for six months. Findings revealed no drug-
related toxicity [10]. It was recommended that glipizide is in the dose range of 2.5 - 20 mg daily. 
The highest therapeutic dose of glipizide is 40 mg daily. Gradual dosage adjustment usually is 
required for patients [11].  
 
 
Figure 1. Structure of glipizide. 
Glipizide has been synthesized in our laboratory in Vietnam Institute of Industrial 
Chemistry. Its synthetic procedure had been previously published [12]. The synthesis of 
glipizide included three steps starting from commercially available 5-methylpyrazine-2-
cacboxylic acid, with overall yield of 56 %. The structures of glipizide were determined by IR, 
MS and NMR spectroscopic methods and its qualities met the USP-40 (The United States 
Phamarcopeia). In this continuous study, we report the results of acute and subacute toxicity of 
glipizide, which was produced in our laboratory, on BALB/c albino mice.  
2. MATERRIAL AND METHODS 
2.1. Sample preparation 
Glipizide was obtained from the laboratory of Vietnam Institute of Industrial Chemistry 
according to method as published in the paper [12]. Purity: 98.5 %, mp: 205 
o
C, insoluble in 
water, partly soluble in CHCl3 and EtOH. White powder product was packed in sealed PE bags.  
2.2. Animal 
Healthy BALB/c mice in range of 19-22 gram were used in acute and subacute toxicity 
experiment. Mice were grown in light and temperature standard condition at Institute of 
Biotechnology. They were obtained food and water ad bilitum.  
2.3 Experiments 
2.3.1. Acute toxicity 
Mice were weighed and divided to 5 groups (10 mice/group) and fasted overnight before 
treatment. Group 1 served as physiological control in which mice were administered 0.3 ml 
distilled water. Group 2, 3, 4 and 5 were treated with glipizide at a single oral dose of 2000, 
3000, 4000 and 5000 mg/kg b.w, respectively. All the animals were objected for the clinical 
signs and weighed for the first  2 hours, 1 day, 4 day and 7 day after treatment. The mortality 
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was also recorded for 3 days. The LD50 (Lethal dose at 50 percent) of sample was calculated by 
using Karber Behrens formular as following [13, 14]:  
LD50 = LD100 - Σa×b/N 
in which: LD50 is the amount of the sample required to kill 50 % of the tested animal population. 
LD100 is the lowest dose of sample inducing 100 % of animal death, N is the number of animals 
in each group; a is the dose different while b is the mean of mortality. 
2.3.2. Subacute toxicity 
 Based on the result of acute toxicity test, 24 mice were divided into 4 groups. Mice in 
group 1 were administered only distilled water and served as control group. The experimented 
groups 2, 3, 4 were treated orally glipizide at doses of 125, 250 and 500 mg/kg b.w, respectively, 
for 4 weeks at specific time daily. All experiment animals were observed daily for the mortality 
and any clinical signs and symptoms, the behavior alteration, food and water intake. In addition, 
the body weight of tested mice was also recorded once a week. 
At the end of experiment, the blood samples were collected from orbital sinus for 
haematological and biochemical parameters. The haematological indexes were studied including 
red blood cell count, white blood cell count, platelet count, hemoglobin, mean corpuscular 
volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration by 
using a hematology analyzer. For biochemical analysis, the serum was separated from the blood 
sample and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine 
were estimated by using a semi-automated Biochemical Analyzer.  
After blood collection, mice were sacrificed and the organs (liver, kidney and spleen) were 
dissected, washed in saline solution and weighed. 
2.3.3. Data analysis 
The data were expressed as Mean ± SE. The results were analyzed statistically by Student 
t’ Test, one-way Analysis of Variance (ANOVA). The P < 0.05 was considered to be 
statistically significant in comparison  with control. 
3. RESULTS AND DISCUSSIONS 
3.1. Acute cytotoxic 
There was no toxicity and mortality observation in mice treated with glipizide. None of 
mice showed the toxic clinical signs in behavior, skin, fur, eyes or diarrhea. The sign of tremors, 
convulsion, lethargy, sleep and coma did not reported in testing mice. During 7 days of 
observation, the food consumption and water intake at all dose treatment were also similar to 
control group. 
Beside clinical observation, the body weight of mice was also determined. As showed in 
Table 1, the body weight of mice was totally similar between control group and test groups. 
After glipizide administration, the body weight gradually increased in various time points. 
However, the body weight of all tested groups was not significantly different from control group 
(P > 0.05). From these results, glipizide showed the LD50 to be much higher than 5000 mg/kg 
b.w. 
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According to the World Health Organization and Organization for Economic Cooperation 
and Development – OECD [15, 16], of which object possesses LD50 greater than 5000 mg/kg 
b.w. could be assigned as Class 5 and considered as non toxic or at the lowest toxic potent. 
Table 1. The effect of glipizide on body weight of mice in acute toxicity test. 
Groups Mean of body weight (gr) 
Day 0 Day 1st Day 4th Day 7th 
Control 
group 
Mean ±SE 20.58 ± 0.44 20.77 ± 0.41 21.27 ± 0.40 21.83 ± 0.34 
P value - - - - 
Group 2 Mean ± SE 20.83 ± 0.54 21.00 ± 0.57 21.47 ± 0.58 22.05 ± 0.56 
P value > 0.05 > 0.05 > 0.05 > 0.05 
Group 3 Mean ± SE 20.42 ± 0.30 20.47 ± 0.38 20.78 ± 0.48 21.86 ± 0.30 
P value > 0.05 > 0.05 > 0.05 > 0.05 
Group 4 Mean ± SE 20.42 ± 0.24 20.52 ± 0.26 20.82 ± 0.33 21.85 ± 0.61 
P value > 0.05 > 0.05 > 0.05 > 0.05 
Group 5 
 
Mean ± SE 20.47 ± 0.31 20.10 ± 0.32 20.73 ± 0.34 21.90 ± 0.33 
P value > 0.05 > 0.05 > 0.05 > 0.05 
(LD50 > 4000 mg/kg) (up to 8 mg/kg/day for six months). 
3.2. Subacute toxicity test 
3.2.1. Observation 
Table 2. The change of body weight of glipizide treated mice in sub-acute toxicity test. 
Groups 
Mean of body weight (gr) 
Day 0 Day 7th Day 14th Day 21st Day 28th 
Control 
group 
Mean ± SEM 21.20 ± 0.52 22.87 ± 0.22 26.23 ± 0.81 27.49 ± 0.77 28.33 ± 0.81 
P value - - - - - 
Group 2 
Mean ± SEM 21.2 ± 1.12 22.23 ± 1.36 24.87 ± 1.67 26.9 ± 2.15 28.1 ± 1.16 
P value > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
Group 3 
Mean ± SEM 21.3 ± 0.46 22.32 ± 0.52 24.25 ± 0.44 26.2 ± 0.44 27.6 ± 0.57 
P value > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
Group 4 
Mean ± SEM 21.8 ± 0.55 22.30 ± 0.83 24.28 ± 0.70 26.1 ± 0.80 27.1 ± 0.91 
P value > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 
In order to determine subacute toxic effects of glipizide, mice were daily treated with 
different doses of glipizide based on the result of acute toxicity test. During the 28 – day period 
of glipizide administration, there were no signs of abnormal change in skin, fur paten, eyes and 
behavior of glipizide treated mice. All of animals also were alive in experiment period of time.  
 
 
Acute and subacute toxic study on mice of glipizide synthesized in Viet Nam  
 
19 
The body weights of mice were recorded on initial day, 7
th
, 14
th
, 21
st
 and 28
th
 day. Glipizide 
did not show strong effects on the growth of mice (Table 2). The body weight of glipizide 
treated mice continuously increased in the experiment duration. Although the body weight of 
mice treated with high dose (500 mg/kg) and medium dose (250 mg/kg) of glipizide was slightly 
lower than that of mice in control group by end of the experiment, there was no significantly 
different (P > 0.05). 
3.2.2. Hematological and biological parameters   
Table 3. The affect of glipizide on hemalogical and biological parameter. 
Parameter Control Group 2 Group 3 Group 4 
WBC 
( 10
9
/L) 
Mean ± SE 8.23 ± 0.13 8.34± 0.21 8.36±0.14 8.34±0.14 
P value - > 0.05 > 0.05 > 0.05 
RBC 
( 10
12
/L) 
Mean ± SE 8.68 ± 0.21 8.72±0.45 8.91±0.18 8.87±0.20 
P value - > 0.05 > 0.05 > 0.05 
Hemoglobin 
(g/L) 
Mean ± SE 132.83±2.77 133.23 ± 2.08 133.17 ± 2.54 134.33 ± 1.69 
P value - > 0.05 > 0.05 > 0.05 
HCT (fl) 
Mean ± SE 0.44 ± 0.01 0.44 ± 0.02 0.43 ± 0.01 0.44 ± 0.01 
P value - > 0.05 > 0.05 > 0.05 
MCV (g/L) 
Mean ± SE 49.27 ±  0.76 49.25 ± 0.41 49.20 ± 0.62 49.08 ± 0.82 
P value - > 0.05 > 0.05 > 0.05 
MCH (pg) 
Mean ± SE 14.95 ± 0.27 14.82 ±  0.32 14.97 ± 0.14 14.77 ± 0.28 
P value - > 0.05 > 0.05 > 0.05 
MCHC (g/L) 
Mean ± SEM 292.17 ± 5.38 296.17 ± 3.18 300.17 ± 4.47 300.50 ± 3.68 
P value - > 0.05 > 0.05 > 0.05 
PLT ( 10
9
/L) 
Mean ± SE 804.00 ± 10.95 791.58 ± 12.26 782.33 ± 13.58 789.33 ± 10.47 
P value - > 0.05 > 0.05 > 0.05 
AST UI/L) 
Mean ± SE 88.93 ± 2.15 92.69 ± 1.32 94.37 ± 1.30 98.78* ± 1.69 
P value - > 0.05 > 0.05 < 0.05 
ALT (UI/L) 
Mean ± SE 42.40 ± 1.05 42.33 ± 0.64 42.10 ± 0.73 41.83 ± 0.87 
P value - > 0.05 > 0.05 > 0.05 
Creatinin 
(UI/L) 
Mean ± SE 26.83 ± 0.63 27.06 ± 0.47 27.95 ± 0.53 30.12 ± 0.61 
P value - > 0.05 > 0.05 > 0.05 
Note: *P<0.05 in comparision with that of control group. 
The effect of glipizide on haematological index was presented in Table 3. The indices 
including red blood cells, total white blood cells, platelet counts, hemoglobin, hematocrit, the 
mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and 
mean corpuscular hemoglobin (MCH) in blood of all tested mice were similar to those of control 
group.  
Liver and kidney are toxic cleavage organs in the body. Therefore, the effect of glipizide on 
liver and kidney function was accessed by determining alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and creatin phosphokinase (CPK) levels in serum. The results 
from Table 3 showed that glipizide had no effect on level of CPK, a kidney function enzyme or 
ALT, a biomarker of hepatic damage. However, the AST level was slightly increased at 500 
mg/kg b.w glipizide treated mice (P < 0.05). The AST level increases in blood when the liver 
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was affected and damaged in some manner. This enzyme could be used for the safety evaluation 
of developmental compounds in the pharmaceutical industry [17]. The higher AST level in 500 
mg/kg b.w. glipizide treated mice indicated that high dose of glipizide  for long time may affect 
the liver function.   
3.2.3. The change of organs’ weight 
The assessment of organs’ weight in toxicity test is an essential process in evaluating 
pharmaceuticals. The toxicity of drug may relate to the change of organs’ weight. The changes 
are often accompanied by corresponding histopathological findings [18]. 
Liver and kidney are the major organs which have detoxification and excretion functions. 
Spleen also plays an important role in the immunological activities. As shown in the Table 4, 
glipizide did not effect on the relative organ weights of liver, spleen or kidney at different doses 
when compared with control (P > 0.05). On the other hand, neither lesion nor necrosis was 
observed in liver, spleen or kidney. There was also no water retention in kidney. Therefore, the 
samples were not collected for histopathological assessment. 
Table 4. Relative organ weights of mice treated glipizide (gram/10 gram b.w). 
Groups Relative organs weight (gram/10 gram b.w) 
liver kidney spleen 
Control Mean 
±SEM 
0.385 ± 0.018 0.095 ± 0.015 0.034 ± 0.014 
P value - - - 
Group 2 Mean 
±SEM 
0.384 ± 0.022 0.095 ± 0.021 0.035 ± 0.012 
P value > 0.05 > 0.05 > 0.05 
Group 3 Mean  ± 
SEM 
0.383 ± 0.021 0.094 ± 0.019 0.035 ± 0.022 
P value > 0.05 > 0.05 > 0.05 
Group 4 Mean  ± 
SEM 
0.387 ± 0.016 0.096 ± 0.024 0.035 ± 0.017 
P value > 0.05 > 0.05 > 0.05 
4. CONCLUSIONS 
All obtained results from our study report that the synthesized glipizide at all different 
tested dosages is safe with no signs of acute toxicity. The LD50 was much greater than the 
highest usage dose which was 5000 mg/kg b.w. since no death of animal was recorded at this 
dose. Also, in the subacute toxic test, the glipizide treated mice showed no change in body 
weights, in haematological and biochemical parameters as well as in relative organ weights. 
However, the AST level in the 500 mg/kg b.w. glipizide treated group exhibited higher number 
meaning of liver partially damaged.   
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